DocDollars

Actelion Pharmaceuticals Us, Inc.

CA · United States · Reporting entity ID 100000010813

Total reported 2019–2025
$25.7M
#273 of 2,960 reporting companies — 0% of all reported industry payments
$24.5M in general payments across 177,444 records, plus $1.13M in research funding across 216 records.

How it breaks down

General payments $24,532,588
Research funding $1,128,534

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Actelion Pharmaceuticals Us, Inc. reported $25.7M to US doctors and teaching hospitals from 2019 to 2025, ranking #273 of 2,960 reporting companies. 4% of that was research funding and 96% general payments such as consulting, speaking, food and travel. 177,444 general payment records and 216 research records were filed.

Common questions about Actelion Pharmaceuticals Us, Inc.

How much has Actelion Pharmaceuticals Us, Inc. paid US doctors?

Actelion Pharmaceuticals Us, Inc. reported $25,661,122 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $24,532,588 in general payments, $1,128,534 in research funding.

How does Actelion Pharmaceuticals Us, Inc. rank among drug and device companies?

It ranks #273 of 2,960 reporting entities by total reported value, about 0% of all industry payments in the dataset.

Does a payment from Actelion Pharmaceuticals Us, Inc. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.